Table 4.

Assessment of P2Y12 responsiveness in patients treated without and with PPIs (multiplicative model).

	Multiplicative Model
Criteria in Defining LTPR	Crude OR (95% CI)	P value	Adjusted OR (95% CI)†	P value
(1) Criteria by inhibition >20%
All PPIs	1.28 (0.74–2.20)	.3814	1.15 (0.65–2.04)	.6295
Individual PPI
Lansoprazole	0.98 (0.49–1.94)	.9426	0.89 (0.44–1.81)	.7406
Dexlansoprazole	3.20 (1.19–8.62)	.0212∗	2.78 (0.99–7.74)	.0503
Pantoprazole	1.37 (0.48–3.92)	.5540	1.26 (0.43–3.64)	.6744
Esomeprazole	1.60 (0.54–4.78)	.3980	1.47 (0.49–4.44)	.4959
Rabeprazole	0.36 (0.07–1.83)	.2168	0.31 (0.06–1.63)	.1655
(2) Criteria by PRU < 235
All PPI	1.43 (0.81–2.52)	.2137	1.20 (0.67–2.17)	.5427
Individual PPI
Lansoprazole	1.29 (0.63–2.64)	.4841	1.10 (0.53–2.229)	.8058
Dexlansoprazole	2.05 (0.85–4.97)	.1119	1.63 (0.65–4.10)	.2960
Pantoprazole	2.05 (0.72–5.86)	.1804	1.80 (0.62–5.22)	.2822
Esomeprazole	1.79 (0.61–5.30)	.2901	1.53 (0.51–4.61)	.4467
Rabeprazole	0.29 (0.04–2.46)	.2583	0.23 (0.03–1.99)	.1834
(2) Criteria by PRU < 262
All PPIs	1.42 (0.79–2.56)	.2472	1.13 (0.61–2.10)	.6901
Individual PPI
Lansoprazole	1.13 (0.53–2.42)	.7512	0.91 (0.41–1.99)	.8058
Dexlansoprazole	2.70 (1.10–6.60)	.0297∗	1.93 (0.76–4.86)	.1651
Pantoprazole	1.62 (0.55–4.80)	.3858	1.80 (0.62–5.22)	.2822
Esomeprazole	1.80 (0.59–5.44)	.2990	1.45 (0.47–4.50)	.5230
Rabeprazole	0.39 (0.05–3.25)	.3808	0.28 (0.03–2.35)	.2386

LTPR = low on-treatment platelet reactivity, OR = odds ratio, PPI = proton pump inhibitor. Model adjusted using the covariate of dual antiplatelet use.

^∗Statistical significance (P <.05).

^†Model was adjusted using covariate of dual antiplatelet use.